ArticleJournal of nanobiotechnology2026
Glycosylated nanoparticles for oral insulin delivery via glucose transporter to improve intestinal absorption.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Oral administration offers significant advantages for insulin delivery, including improved patient compliance and convenience compared to injectable formulations. However, the therapeutic potential of oral insulin delivery is nevertheless constrained by multiple physiological barriers including gastrointestinal enzymatic degradation, mucus layer entrapment, and limited epithelial permeability. To protect against gastrointestinal degradation and promote penetration across the intestinal barrier, we developed glucose-modified PLGA-lipid hybrid nanoparticles through a sequential fabrication process involving insulin encapsulation in PLGA cores via W1/O/W2 double emulsion followed by surface functionalization with glycosylated lipids using film hydration-ultrasonication. The resulting core-shell nanoparticles combined protective and absorptive functions by maintaining insulin stability under gastric conditions while enabling pH-responsive intestinal release, with surface glucose moieties facilitating enhanced cellular uptake through glucose transporter-mediated pathways. In a type 1 diabetes mouse model this nanoparticle system demonstrated superior therapeutic outcomes, supporting its potential as an effective oral insulin delivery platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.